A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
Clinical trial NCT04562116 · COMPLETED
Trial details
- NCT number
- NCT04562116
- Sponsor
- Galderma R&D
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-08
- Primary completion
- 2023-06-07
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.